Dieta Brandsma

Dieta Brandsma

Auto-generated profile, based on publicly available information

Dieta Brandsma

Department of Neuro-Oncology, Netherlands Cancer Institute , Amsterdam

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
EREmilie Le Rhun
Emilie Le Rhun
PDPatrick Devos
Patrick Devos
JWJohannes Weller
Johannes Weller
KSKatharina Seystahl
Katharina Seystahl
FMFrancesca Mo
Francesca Mo
MWMichael Weller
Michael Weller
The EANO ESMO guidelines have proposed a classification of leptomeningeal metastases (LM) from solid cancers based on clinical, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) cytology presentation. MRI patterns are classified as linear, nodular, both, or neither. Type I LM is defined by positive CSF cytology (confirmed LM) whereas type II LM is defined by typical clinical and MRI signs (probable or possible LM). Here we explored the clinical utility of these LM subtypes. We retrospectively assembled data from 254 patients with newly diagnosed LM from solid tumors. Survival curves were derived using the Kaplan–Meier method and compared by Log-rank test. Median age at LM diagnosis was 56 years. Typical clinical LM features were noted in 225 patients (89%); 13 patients (5%) were clinically asymptomatic. Tumor cells in the CSF were observed in 186 patients (73%) whereas the CSF was equivocal in 24 patients (9.5%) and negative in 44 patients (17.5%). Patients with confirmed LM had inferior outcome compared with patients with probable or possible LM (P = 0.006). Type I patients had inferior outcome than type II patients (P = 0.002). Nodular disease on MRI was a negative prognostic factor in type II LM (P = 0.014), but not in type I LM. Administration of either intrathecal pharmacotherapy (P = 0.020) or systemic pharmacotherapy (P = 0.0004) was associated with improved outcome in type I LM, but not in type II LM. The EANO ESMO LM subtypes are highly prognostic and should be considered for stratification and overall design of clinical trials.

21 June 2024 in Neuro-Oncology
Verified
Journal Article
Open access
JWJessica A Wilcox
Jessica A Wilcox
UCUgonma N Chukwueke
Ugonma N Chukwueke
MAMyung-Ju Ahn
Myung-Ju Ahn
AAAyal A Aizer
Ayal A Aizer
TBTejus A Bale
Tejus A Bale
ABAdrienne A Boire
Adrienne A Boire
Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer, specifically in patients with parenchymal brain metastases, treatment options, and clinical research protocols for patients with LM from solid tumors have similarly evolved to improve survival within specific populations. Recent expansions in clinical investigation, early diagnosis, and drug development have given rise to new unanswered questions. These include leptomeningeal metastasis biology and preferred animal modeling, epidemiology in the modern cancer population, ensuring validation and accessibility of newer leptomeningeal metastasis diagnostics, best clinical practices with multimodality treatment options, clinical trial design and standardization of response assessments, and avenues worthy of further research. An international group of multi-disciplinary experts in the research and management of LM, supported by the Society for Neuro-Oncology and American Society of Clinical Oncology, were assembled to reach a consensus opinion on these pressing topics and provide a roadmap for future directions. Our hope is that these recommendations will accelerate collaboration and progress in the field of LM and serve as a platform for further discussion and patient advocacy.

12 November 2015 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
BKBojana Milojkovic Kerklaan
Bojana Milojkovic Kerklaan
DPDick Pluim
Dick Pluim
MBMijke Bol
Mijke Bol
IHIngrid Hofland
Ingrid Hofland
JWJohan Westerga
Johan Westerga
DBDieta Brandsma
Dieta Brandsma
Moderate diagnostic accuracy of MRI and initial cerebrospinal fluid (CSF) cytology analysis results in at least 10%–15% false negative diagnoses of leptomeningeal metastases (LM) of solid tumors, thus postponing start of therapy. The aim of this prospective clinical study was to determine the diagnostic value of epithelial cell adhesion molecule (EpCAM)–based flow cytometry versus cytology in CSF for the diagnosis of LM in patients with epithelial tumors. Patients with a clinical suspicion of LM but a negative or inconclusive MRI in whom a diagnostic lumbar puncture has to be performed were included. At least 5 mL of CSF for cytology, 5 mL for flow cytometry, 2 mL for cell count and biochemistry, and 8 mL whole blood samples for circulating tumor cells measurements and biochemistry were drawn. Tumor cells in CSF and whole blood were detected by multiparameter flow cytometry using EpCAM antibody. In total 29 eligible patients were enrolled in the study. Thirteen patients were ultimately diagnosed with LM. The flow cytometry assay showed 100% sensitivity and 100% specificity for diagnosing LM, while sensitivity of CSF cytology was only 61.5%. Cell count or biochemical parameters in CSF were abnormal in 100% of patients with LM. Our results suggest that the EpCAM-based flow cytometry assay is superior to CSF cytology for the diagnosis of LM in patients with an epithelial tumor, a clinical suspicion of LM, and a nonconclusive MRI. Confirmation of these data is needed in a larger dataset to recommend dual CSF diagnostics for LM. NCT01713699.


4 February 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
MBMark T.J. van Bussel
Mark T.J. van Bussel
DPDick Pluim
Dick Pluim
BKBojana Milojkovic Kerklaan
Bojana Milojkovic Kerklaan
MBMijke Bol
Mijke Bol
KSKarolina Sikorska
Karolina Sikorska
DBDieta Brandsma
Dieta Brandsma
Objective The primary objective was to determine the sensitivity and specificity of epithelial cell adhesion molecule (EpCAM) immunoflow cytometry circulating tumor cells (CTC) analysis in CSF in patients with suspected leptomeningeal metastases (LM). The secondary objective was to explore the distribution of driver mutations in the primary tumor, plasma, cell free CSF (cfCSF), and isolated CTC from CSF in non-small cell lung cancer (NSCLC). Methods We tested the performance of the CTC assay vs CSF cytology in a prospective study in 81 patients with a clinical suspicion of LM but a nonconfirmatory MRI. In an NSCLC subcohort, we analyzed circulating tumor (ct)DNA of the selected driver mutations by digital droplet PCR (ddPCR). Results The sensitivity of the CTC assay was 94% (95% confidence interval [CI] 80–99) and the specificity was 100% (95% CI 91–100) at the optimal cutoff of 0.9 CTC/mL. The sensitivity of cytology was 76% (95% CI 58–89). Twelve of the 23 patients with NSCLC had mutated epidermal growth factor receptor (EGFR). All 5 tested patients with LM demonstrated the primary EGFR driver mutation in cfCSF. The driver mutation could also be detected in CTC isolated from CSF. Conclusion CTC in CSF are detected with a high sensitivity for the diagnosis of LM. ddPCR can determine EGFR mutations in both cfCSF and isolated CTC from CSF of patients with EGFR-mutated NSCLC and LM. Classification of evidence This study provides Class III evidence that EpCAM-based immunoflow cytometry analysis of CSF accurately identifies patients with LM.

30 November 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MBMark T. J. van Bussel
Mark T. J. van Bussel
DPDick Pluim
Dick Pluim
MBMijke Bol
Mijke Bol
JBJos H. Beijnen
Jos H. Beijnen
JSJan H. M. Schellens
Jan H. M. Schellens
DBDieta Brandsma
Dieta Brandsma